Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 8/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.44 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10937318 | 1.00 | ITGB3 (0.44) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 | |
| SCHEMBL26126284 | 1.00 | ITGB3 (0.44) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 | |
| SCHEMBL7893552 | 0.97 | ITGB3 (0.47) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 | |
| SCHEMBL7257726 | 0.96 | ITGB3 (0.48) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 | |
| Methoxymethane SCHEMBL2940968 | 0.95 | ITGB3 (0.46) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 | |
| SCHEMBL7887537 | 0.95 | ITGB3 (0.50) | ITGB3ITGA2BSLC15A2SLC6A5 | |
| SCHEMBL4653518 | 0.95 | ITGB3 (0.50) | ITGB3ITGA2BSLC15A2SLC6A5 | |
| SCHEMBL8630043 | 0.95 | ITGB3 (0.50) | ITGB3ITGA2BSLC15A2SLC6A5 | |
| Carnosine SCHEMBL33768 | 0.92 | ITGB3 (0.41) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 | |
| Carnosine SCHEMBL3904964 | 0.92 | ITGB3 (0.41) | ITGB3ITGA2BSLC15A2SLC6A5CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4469034-A1 | COMPOSITION FOR TREATING ESOPHAGEAL REFLUX | Metis Healthcare S.r.L. (IT) | 2024-12-04 | — | — | EP | claimed |
| EP-3328409-B1 | COMPOSITION FOR THE INCREASE OF HUMORAL SECRETION | METIS HEALTHCARE S R L (IT) | 2023-08-23 | — | — | EP | claimed |
| US-10646476-B2 | Method for treatment of humoral secretion dysfunctions | METIS HEALTHCARE S.R.L. (IT) | 2020-05-12 | — | — | US | claimed |
| US-20180207134-A1 | COMPOSITION FOR THE INCREASE OF HUMORAL SECRETION | METIS HEALTHCARE S.R.L. (IT) | 2018-07-26 | — | — | US | claimed |
| EP-4097145-B1 | REDUCTION OF ADSORPTION | LEUKOCARE AG (DE) | 2026-01-28 | — | — | EP | disclosed |
| EP-4640838-A1 | UTILIZATION OF MESENCHYMAL STEM CELLS OR CULTURE SUPERNATANT THEREOF | Cell Exosome Therapeutics Inc. (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-12350375-B2 | Method for obtaining efficient viral vector-based compositions for vaccination or gene therapy | LEUKOCARE AG (DE) | 2025-07-08 | — | — | US | disclosed |
| US-12083204-B2 | Topical composition for homeostatic delivery of nitric oxide and uses thereof | L'OREAL (FR) | 2024-09-10 | — | — | US | disclosed |
| WO-2024135853-A1 | UTILIZATION OF MESENCHYMAL STEM CELLS OR CULTURE SUPERNATANT THEREOF | Ｃｅｌｌ Ｅｘｏｓｏｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 | 2024-06-27 | — | — | WO | disclosed |
| US-12011496-B2 | Topical macqui berry formulation | Tracie Martyn International, Inc. (US) | 2024-06-18 | — | — | US | disclosed |
| WO-2023233383-A2 | TOPICAL COMPOSITION FOR HOMEOSTATIC DELIVERY OF NITRIC OXIDE AND USES THEREOF | L'OREAL (FR) | 2023-12-07 | — | — | WO | disclosed |
| US-20230390172-A1 | TOPICAL COMPOSITION FOR HOMEOSTATIC DELIVERY OF NITRIC OXIDE AND USES THEREOF | Dermaforce Holdings, LLC | 2023-12-07 | — | — | US | disclosed |
| EP-0962453-A1 | Histidine derivatives, process for their preparation and their uses | L'OREAL (FR) | 1999-12-08 | — | — | EP | disclosed |
| WO-1999047504-A1 | NOVEL HISTIDINE DERIVATIVES PREPARATION METHOD AND USES | L'OREAL (FR) | 1999-09-23 | — | — | WO | disclosed |
| US-5561110-A | ADMINISTERING OLIGOPEPTIDE | PEPTIDE TECHNOLOGY LIMITED (AU) | 1996-10-01 | — | — | US | disclosed |
| EP-0666753-A1 | METHOD FOR THE TREATMENT OF THE COMPLICATIONS AND PATHOLOGY OF DIABETES | PEPTIDE TECHNOLOGY LTD (AU) | 1995-08-16 | — | — | EP | disclosed |
| EP-0666753-A4 | METHOD FOR THE TREATMENT OF THE COMPLICATIONS AND PATHOLOGY OF DIABETES. | PEPTIDE TECHNOLOGY LTD (AU) | 1995-01-26 | — | — | EP | disclosed |
| WO-1993004690-A1 | METHOD FOR THE TREATMENT OF THE COMPLICATIONS AND PATHOLOGY OF DIABETES | PEPTIDE TECHNOLOGY LIMITED (AU) | 1993-03-18 | — | — | WO | disclosed |
| US-4529602-A | Sulfodehydroabietic acid compound | TANABE SEIYAKU CO., LTD. (JP) | 1985-07-16 | — | — | US | disclosed |
| US-3995051-A | HISTIDINES | STANLEY DRUG PRODUCTS, INC. (US) | 1976-11-30 | — | — | US | disclosed |